STOCK TITAN

Painreform Ltd - PRFX STOCK NEWS

Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.

Company Overview

PainReform Ltd is a clinical-stage specialty pharmaceutical company dedicated to the reformulation of established pain therapeutics. With a focus on innovation within the postoperative analgesia and extended-release drug-delivery space, the company is committed to transforming pain management for both physicians and patients. By leveraging the FDA 505(b)(2) regulatory pathway, PainReform aims to enhance the clinical efficacy of existing medications while reducing adverse effects and optimizing dosing convenience.

Core Technologies and Therapeutic Advances

PainReform’s portfolio is anchored by its lead product candidate, PRF-110, which is based on the local anesthetic ropivacaine. Utilizing a proprietary, oil-based, viscous solution, PRF-110 is deposited directly into the surgical wound bed prior to closure. This innovative approach ensures localized, extended postoperative analgesia by maintaining therapeutic drug concentrations at the site of tissue injury over an extended period. The formulation addresses common limitations of traditional pain management therapies by reducing the necessity for repeated dosing and potentially lowering reliance on opioids.

Operational Strategy and Market Position

The company operates within the niche of drug reformulation, addressing specific clinical needs within the pain management segment. Through its disciplined focus on reformulating proven therapeutics, PainReform differentiates itself by applying unique technologies that enhance drug performance and patient compliance. The company’s operational model blends ongoing clinical research with strategic process improvements designed to bolster future commercialization efforts, thereby ensuring a resilient market presence in a dynamic therapeutic landscape.

Competitive Landscape and Differentiating Factors

PainReform competes in a complex landscape where innovation in drug delivery systems is critical to success. Unlike companies that develop entirely new molecular entities, PainReform capitalizes on reformulating established therapies to improve their safety and efficacy profiles. This approach allows the company to navigate regulatory pathways more efficiently while providing significant clinical benefits. Its extended-release technology is a key differentiator, offering both a therapeutic and operational advantage in a competitive market characterized by high standards of care and rigorous regulatory oversight.

Product Focus and Clinical Advantages

At the heart of PainReform’s clinical efforts is PRF-110, a product designed to address the unmet need for sustained postoperative pain relief. The product's oil-based, clear solution enables a streamlined mode of application and controlled drug release, tailoring pain management to the procedural landscape. By depositing the medication directly into the surgical wound bed, the company’s strategy minimizes the potential for systemic side effects and improves the overall patient experience. This method supports a growing clinical consensus that targeted, extended-release formulations can substantially improve postoperative recovery trajectories.

Industry Insights and Technological Integration

Within the specialty pharmaceutical sector, the intersection of drug reformulation and advanced delivery platforms represents a significant area of innovation. PainReform’s approach reflects a broader industry trend that prioritizes patient-centric therapies designed to deliver tangible clinical improvements. The integration of advanced drug-delivery systems not only refines the pharmacokinetic profile of established agents but also reinforces the company’s commitment to clinical excellence and operational efficiency. By adhering to rigorous regulatory standards and leveraging industry expertise, PainReform continues to evolve its technology platform, setting benchmarks in extended-release formulations and targeted therapeutic interventions.

Commitment to Quality and Clinical Validation

PainReform’s development strategy is reinforced by a commitment to clinical validation and quality assurance. Robust compatibility studies and ongoing clinical trials underscore the safety and efficacy of its formulations, positioning the company as a trusted entity within the pharmaceutical research community. Each phase of development is guided by stringent quality controls and backed by scientific data, ensuring that the therapeutic benefits of its products are communicated clearly to healthcare professionals and regulatory bodies alike.

Summary

In summary, PainReform Ltd stands as a specialist in the reformulation of pain therapeutics, harnessing innovative extended-release drug-delivery systems to address postoperative pain. Its focused approach, centered around PRF-110 and similar candidates, positions the company favorably within a competitive and evolving market. With an emphasis on clinical benefits, operational efficiency, and regulatory compliance, PainReform continues to advance a portfolio that is both strategic and clinically transformative, ensuring that it meets the essential needs of modern pain management.

Rhea-AI Summary

PainReform (NASDAQ: PRFX) has completed its acquisition of DeepSolar, an AI-driven solar analytics platform, from BladeRanger The acquisition positions PainReform in the high-growth clean energy sector while maintaining its pharmaceutical focus.

DeepSolar's SaaS platform provides AI-powered solutions for solar energy asset management, promising to reduce maintenance costs by up to 30%. The platform integrates with SCADA systems for monitoring and predictive maintenance, targeting utility-scale operators, power producers, and residential users.

As consideration, BladeRanger received 178,769 ordinary shares (9.9% of PainReform) and 223,792 pre-funded warrants. Additional securities will be issued after the April 3, 2025 shareholders meeting, including milestone warrants and warrants-A/B, with a 9.99% ownership cap.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
-
Rhea-AI Summary

PainReform (PRFX) has executed a definitive agreement to acquire DeepSolar, an AI-driven solar analytics platform, from BladeRanger The acquisition, expected to close by February 2025, represents a strategic expansion while maintaining the company's commitment to drug delivery technologies.

DeepSolar's AI-powered platform optimizes solar energy assets, reducing operational costs by up to 30% and maximizing energy production. The platform serves both B2B (utility-scale operators) and B2C (residential) markets through its 'My DeepSolar' app.

As consideration, BladeRanger will receive 178,769 ordinary shares (9.9% of PainReform), plus various warrants totaling over 3 million potential shares. The agreement includes a 9.99% ownership cap and a 90-day restriction on new share issuances by PainReform. The company must register these securities with the SEC within 60 days of closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.56%
Tags
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) provided an update on its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients. While the trial showed statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery, the company revealed that data from the final 24-hour period could not be clarified to meet the study's primary endpoint 72-hour requirement. As a result, the trial did not achieve its primary endpoint.

The company has initiated R&D activities to better understand and refine PRF-110's pharmaco-kinetics and pharmaco-dynamics based on study data. Management plans to use high-level, in-vitro models to address the 72-hour requirement issue before conducting additional clinical work. The company is also reviewing strategic options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
Rhea-AI Summary

PainReform (Nasdaq: PRFX) announced partial topline data from its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients. The initial analysis shows statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery. However, data for the subsequent 24-hour period, important for the primary endpoint assessment, remains unclear due to data incoherence. The company is working with Lotus Clinical Research to resolve these data issues. PRF-110 is an oil-based, extended-release formulation of ropivacaine, designed to provide prolonged pain relief while reducing opioid dependency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.71%
Tags
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement. The company no longer meets the $2.5 million stockholders' equity threshold, the $35 million market value requirement, or the alternative $500,000 net income criteria. PainReform has until December 19, 2024, to submit a compliance plan to Nasdaq. If accepted, the company may receive an extension until May 3, 2025, to regain compliance. The notification does not immediately affect the listing or trading of shares on the Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has announced positive results regarding the compatibility of sutures in human clinical trials for its lead product, PRF-110. The company conducted in vitro studies to assess the impact of PRF-110 on both non-absorbable and resorbable sutures, specifically PROLENE™ and Vicryl™. The results showed that PRF-110 does not affect the mechanical properties of these sutures, including breaking force and elongation, after 14 days of exposure.

This finding is consistent with the phase III clinical results from the bunionectomy trial and supports the safety and efficacy of PRF-110 in post-surgical pain management. The compatibility of PRF-110 with surgical sutures is a significant advancement in post-operative care, as it allows for extended, non-opiate pain relief without compromising suture integrity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.38%
Tags
Rhea-AI Summary

PainReform (Nasdaq: PRFX), a clinical-stage pharmaceutical company, has announced agreements for the immediate exercise of outstanding warrants. These warrants, originally issued in December 2023 and April 2024, will purchase up to 989,300 ordinary shares at a reduced price of $1.60 per share, down from the original $4.80. The offering is expected to close around September 11, 2024.

In exchange for this exercise, PainReform will issue new unregistered warrants for up to 1,978,600 ordinary shares, exercisable immediately at $1.60 per share and expiring in five years. The company anticipates gross proceeds of approximately $1.58 million from this transaction, which will be used for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
none
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has successfully determined the optimal delivery method for PRF-110 in bunionectomy procedures, marking a significant milestone in advancing post-surgical pain management. Phase III evaluations have demonstrated PRF-110's superior physical properties, ensuring optimal coverage of cut nerve endings and traumatized tissue surfaces.

Key findings include effective wound coverage, competitive advantages over leading products, enhanced viscosity and uniformity, and precision delivery coverage. PRF-110 exhibited superior adhesion and location adherence compared to competitors, maintaining effectiveness even in the presence of physiological fluids. The product's optimal viscosity and uniformity facilitated ease of application and even distribution across the wound bed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has announced positive early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, a proprietary post-surgical pain formulation. The study, which has completed full enrollment with 443 patients across eight U.S. clinical sites, revealed a low incidence of adverse events, averaging just one per subject.

PRF-110 is positioned as a potential non-opioid alternative in the $12 billion post-operative pain market. The company's Chairman and interim CEO, Ehud Geller, expressed optimism about PRF-110's potential to be a game-changer in post-surgical pain management. The formulation leverages the established safety of ropivacaine and GRAS components, supporting its promising safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.43%
Tags
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has provided a business update for Q2 2024, highlighting significant progress in the clinical development of PRF-110, their lead drug candidate for post-operative pain relief. Key achievements include:

1. Full enrollment (443 patients) in the second part of Phase 3 clinical trial for bunionectomy
2. Favorable wound healing data from human clinical trials
3. Promising PK study results showing safe limits
4. New patent filed for a highly scalable manufacturing process
5. Development of new formulations combining PRF-110 with anti-inflammatory agents

Financial results show increased R&D expenses of $11.4 million, primarily due to the Phase 3 trial. The company's net loss increased to $12.8 million. As of June 30, 2024, PainReform had $2.8 million in cash and cash equivalents, with an additional $4 million raised in April 2024 through a public offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none

FAQ

What is the current stock price of Painreform (PRFX)?

The current stock price of Painreform (PRFX) is $2.24 as of April 1, 2025.

What is the market cap of Painreform (PRFX)?

The market cap of Painreform (PRFX) is approximately 1.9M.

What is the primary focus of PainReform Ltd?

PainReform Ltd is focused on reformulating established pain therapeutics to improve efficacy, safety, and patient convenience. Its lead candidate, PRF-110, exemplifies its commitment to enhanced postoperative pain management.

How does PainReform differentiate its product offerings?

The company differentiates its product portfolio by utilizing a proprietary extended-release drug-delivery system that allows for prolonged localized analgesia. This reduces the need for repeated dosing and potentially lowers opioid requirements.

What regulatory pathway does PainReform utilize for its products?

PainReform leverages the US FDA 505(b)(2) regulatory pathway, which supports the reformulation of established therapeutics by relying on existing data to expedite development.

How does PRF-110 work in managing postoperative pain?

PRF-110 is a viscous, oil-based formulation based on ropivacaine. It is applied directly to the surgical wound bed, providing localized and sustained analgesic effects, thereby enhancing pain relief during the postoperative period.

What are the clinical advantages of PainReform's extended-release formulations?

The extended-release formulations offer sustained therapeutic drug levels at the site of administration, reducing the need for frequent dosing and lowering the risk of systemic side effects. This approach promotes better overall pain management and recovery.

How does PainReform maintain its competitive edge in the specialty pharmaceutical market?

By focusing on reformulation rather than entirely new molecular entities, PainReform benefits from established safety profiles while enhancing clinical performance. Its unique drug delivery innovations and adherence to rigorous regulatory standards further reinforce its competitive position.

What market segment does PainReform primarily serve?

PainReform primarily serves the postoperative pain management segment, addressing a significant need in surgical recovery through its localized and extended-release pain relief solutions.

How does PainReform ensure the quality and efficacy of its products?

Quality and efficacy are ensured through robust clinical research, stringent compatibility studies, and adherence to high regulatory standards. The company’s development process is characterized by ongoing clinical validation and scientific rigor.
Painreform Ltd

Nasdaq:PRFX

PRFX Rankings

PRFX Stock Data

1.93M
1.68M
0.79%
4.58%
7.21%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv